Results 131 to 140 of about 274,076 (393)

Primary prophylaxis of neutropenia in women affected by breast cancer undergoing adjuvant chemotherapy with fec 100+/- docetaxel. Comparison of efficacy and tolerability between lenograstim and pegfilgrastim [PDF]

, 2015
Objectives: evaluate safety and toxicity of a single injection of pegfilgrastim compared to daily administration of lenograstim in breast cancer patient undergoing adjuvant ...
Caruso, Davide, Congedi, Fp, Giannarelli, D, Giordani, Erika, Papa, Anselmo, Ricci, Fabio, Rossi, Luigi Enrico, Tomao, Federica, Verrico, Monica, Zaccarelli, Eleonora   +9 more
core   +1 more source

Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.

Journal of Clinical Oncology, 2015
PURPOSE To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition of clinical stability implies the absence of organ dysfunction, abnormalities in
A. Carmona-Bayonas, P. Jiménez-Fonseca, J. V. Virizuela Echaburu, M. Antonio, C. Font, M. Biosca, A. Ramchandani, Jerónimo Martínez, J. Hernando Cubero, J. Espinosa, E. Martínez de Castro, I. Ghanem, C. Beato, A. Blasco, M. Garrido, Y. Bonilla, R. Mondéjar, M. A. Arcusa Lanza, Isabel Aragón Manrique, A. Manzano, E. Sevillano, E. Castañón, M. Cardona, Elena Gallardo Martín, Quionia Pérez Armillas, F. Sánchez Lasheras, F. Ayala de la Peña   +26 more
semanticscholar   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report

Journal of Medical Case Reports, 2011
Introduction The differential diagnosis of neutropenia includes medications, infections, autoimmune diseases, and deficiencies of Vitamin B12 and folate. The association of Vitamin B6 deficiency with severe neutropenia is a rare finding.
Rauf Mariam, Gleason Charise, Nooka Ajay K, Husman Abbie, Waller Edmund K   +4 more
doaj   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

Cancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai, Tao Fan, Chu Xiao, Ziqin Deng, Yixiao Liu, Chunxiang Li, Jie He   +6 more
wiley   +1 more source

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Hacker, U., Heinemann, Volker, Schalhorn, A., Stemmler, J., Weise, A.   +4 more
core   +1 more source

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

British Journal of Cancer, 2015
Background:Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities.Methods:In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities ...
F. Donskov, M. Michaelson, I. Puzanov, Mellar P. Davis, G. Bjarnason, R. Motzer, D. Goldstein, Xun Lin, D. Cohen, R. Wiltshire, B. Rini   +10 more
semanticscholar   +1 more source

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

Cancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group   +32 more
wiley   +1 more source

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry

RMD Open, 2015
Objectives To evaluate the prevalence of late-onset neutropenia and its complications in patients treated with rituximab (RTX) for rheumatoid arthritis (RA) and other autoimmune diseases (AIDs) in a prospective registry.
J. Salmon, P. Cacoub, B. Combe, J. Sibilia, B. Pallot-Pradès, O. Fain, A. Cantagrel, M. Dougados, Emmanuel Andrès, O. Meyer, P. Carli, E. Pertuiset, I. Pane, F. Maurier, P. Ravaud, X. Mariette, J. Gottenberg   +16 more
semanticscholar   +1 more source